

Jason Karlawish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5688512/publications.pdf>

Version: 2024-02-01

111
papers

9,306
citations

136950

32
h-index

43889

91
g-index

115
all docs

115
docs citations

115
times ranked

10959
citing authors

#	ARTICLE	IF	CITATIONS
1	What is paradoxical lucidity? The answer begins with its definition. <i>Alzheimer's and Dementia</i> , 2022, 18, 513-521.	0.8	13
2	The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment. <i>Social Science and Medicine</i> , 2022, 292, 114620.	3.8	13
3	Is there a difference between terminal lucidity and paradoxical lucidity?. <i>Alzheimer's and Dementia</i> , 2022, 18, 540-541.	0.8	2
4	Predictors of who Serves as an Alzheimerâ€™s Disease Research Participantâ€™s Study Partner and the Impact of their Relationship on Study Partnersâ€™ Reports on Participants. <i>Research on Aging</i> , 2022, 44, 734-746.	1.8	2
5	Supported Decision Making with People at the Margins of Autonomy: Response to Commentaries. <i>American Journal of Bioethics</i> , 2022, 22, W1-W4.	0.9	2
6	Establishing a Framework for Gathering Structural and Social Determinants of Health in Alzheimerâ€™s Disease Research Centers. <i>Gerontologist</i> , The, 2022, 62, 694-703.	3.9	25
7	Disclosing Alzheimer Disease Biomarker Results to Research Participants. <i>JAMA Neurology</i> , 2022, 79, 645.	9.0	11
8	Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab. <i>Drugs and Aging</i> , 2022, 39, 389-400.	2.7	7
9	A Case of Patient Abandonment, or an Abandonment of Patients?. <i>American Journal of Bioethics</i> , 2022, 22, 86-87.	0.9	0
10	â€˜That would be dreadfulâ€™: The ethical, legal, and social challenges of sharing your Alzheimerâ€™s disease biomarker and genetic testing results with others. <i>Journal of Law and the Biosciences</i> , 2021, 8, lsab004.	1.6	18
11	Research Attitudes Questionnaire scores predict Alzheimerâ€™s disease clinical trial dropout. <i>Clinical Trials</i> , 2021, 18, 237-244.	1.6	9
12	Desktop Medicine and the Practice of Wealth Care. <i>JAMA Internal Medicine</i> , 2021, 181, 227.	5.1	0
13	The Future Is P-Tauâ€™ Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests. <i>JAMA Neurology</i> , 2021, 78, 379.	9.0	21
14	Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials. <i>Neurology</i> , 2021, 97, 496-500.	1.1	5
15	Family members' perspectives on learning cognitively unimpaired older adults' amyloidâ€™ ² PET scan results. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 3203-3211.	2.6	12
16	Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases. <i>JAMA Health Forum</i> , 2021, 2, e211428.	2.2	1
17	The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. <i>Nature Reviews Neurology</i> , 2021, 17, 523-524.	10.1	44
18	Participation of persons with dementia and their caregivers in research. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1784-1792.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Aducanumab and the Business of Alzheimer Disease—Some Choice. <i>JAMA Neurology</i> , 2021, 78, 1303.	9.0	5
20	Effectiveness and Ethics of Incentives for Research Participation. <i>JAMA Internal Medicine</i> , 2021, 181, 1479.	5.1	21
21	Application of In-Home Monitoring Data to Transition Decisions in Continuing Care Retirement Communities: Usability Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e18806.	4.3	13
22	Effects of Self-Identification as a Caregiver on Expectations of Public Stigma of Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 31-39.	2.2	5
23	Supported Decision Making With People at the Margins of Autonomy. <i>American Journal of Bioethics</i> , 2021, 21, 4-18.	0.9	43
24	The Collaborative Aging Research Using Technology Initiative: An Open, Sharable, Technology-Agnostic Platform for the Research Community. <i>Digital Biomarkers</i> , 2021, 4, 100-118.	4.4	40
25	Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II). <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1015-1028.	2.6	7
26	The ethical implications of paradoxical lucidity in persons with dementia. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 3617-3622.	2.6	3
27	Please, Don't Fly Me to the Moon. <i>American Journal of Bioethics</i> , 2021, 21, 20-22.	0.9	0
28	Preliminary results from the COVID caregiving project. <i>Alzheimer's and Dementia</i> , 2021, 17, e055199.	0.8	0
29	How knowledge of elevated amyloid impacts neuropsychological performance in cognitively normal older adults: Findings from the REVEAL SCAN Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
30	"Together Make a Visit; Together Make a Plan": Messaging to Adult Children with Concerns about a Parent's Memory Loss. <i>Health Communication</i> , 2020, 35, 512-523.	3.1	3
31	Alive inside. <i>Bioethics</i> , 2020, 34, 295-305.	1.4	16
32	"I Don't Have Time to Sit and Talk with Them": Hospitalists' Perspectives on Palliative Care Consultation for Patients with Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2365-2372.	2.6	5
33	Cognitive Impairment Evaluation and Management. <i>Medical Clinics of North America</i> , 2020, 104, 807-825.	2.5	35
34	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , 2020, 77, 1504.	9.0	48
35	Where Do You End, and I Begin? How Relationships Confound Advance Directives in the Care of Persons Living with Dementia. <i>American Journal of Bioethics</i> , 2020, 20, 83-85.	0.9	4
36	Ethical and Regulatory Issues for Embedded Pragmatic Trials Involving People Living with Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, S37-S42.	2.6	12

#	ARTICLE	IF	CITATIONS
37	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. PLoS ONE, 2020, 15, e0229137.	2.5	61
38	Rescuing Research Participants After Alzheimer Trials Stop Early. JAMA Neurology, 2020, 77, 413.	9.0	7
39	International drive to illuminate delirium: A developing public health blueprint for action. Alzheimer's and Dementia, 2020, 16, 711-725.	0.8	31
40	Caregiving at a Physical Distance: Initial Thoughts for COVID-19 and Beyond. Journal of the American Geriatrics Society, 2020, 68, 1170-1172.	2.6	9
41	Ethics of reallocating ventilators in the covid-19 pandemic. BMJ, The, 2020, 369, m1828.	6.0	36
42	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
43	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
44	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
45	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
46	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
47	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
48	Is the WHO Definition of Health Aging Well? Frameworks for "Health" After Three Score and Ten. American Journal of Public Health, 2019, 109, 1104-1106.	2.7	33
49	Modification of everyday activities and its association with self-awareness in cognitively diverse older adults. PLoS ONE, 2019, 14, e0222769.	2.5	10
50	"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". Alzheimer's and Dementia, 2019, 15, 153-157.	0.8	23
51	Decision-Making Capacity Will Have a Limited Effect on Civil Commitment Practices. American Journal of Bioethics, 2019, 19, 86-88.	0.9	0
52	Paradoxical lucidity: A potential paradigm shift for the neurobiology and treatment of severe dementias. Alzheimer's and Dementia, 2019, 15, 1107-1114.	0.8	36
53	Attitudes Toward Physician-Assisted Death From Individuals Who Learn They Have an Alzheimer Disease Biomarker. JAMA Neurology, 2019, 76, 864.	9.0	15
54	Preclinical Alzheimer Disease and the Dawn of the Pre-Caregiver. JAMA Neurology, 2019, 76, 631.	9.0	20

#	ARTICLE	IF	CITATIONS
55	The Interview for Decisional Abilities (IDA): a tool to assess the decisional capacity of abused and neglected older adults. <i>Journal of Elder Abuse and Neglect</i> , 2019, 31, 244-254.	1.1	5
56	GeneMatch: A novel recruitment registry using at-home <i>APOE</i> genotyping to enhance referrals to Alzheimer's prevention studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 515-524.	0.8	38
57	Social Cognition and the Aging Brain. <i>Annals of Internal Medicine</i> , 2019, 170, 726.	3.9	3
58	Randomized evaluation of trial acceptability by INcentive (RETAIN): Study protocol for two embedded randomized controlled trials. <i>Contemporary Clinical Trials</i> , 2019, 76, 1-8.	1.8	9
59	Alzheimer's Prevention Initiative Generation Program: Development of an <i>APOE</i> genetic counseling and disclosure process in the context of clinical trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 705-716.	3.7	27
60	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.8	5,861
61	What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the U.S. general public. <i>Alzheimer's and Dementia</i> , 2018, 14, 925-932.	0.8	41
62	Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 285-300.	2.4	27
63	Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role. <i>Dementia</i> , 2018, 17, 494-514.	2.0	21
64	Identifiable Characteristics and Potentially Malleable Beliefs Predict Stigmatizing Attributions Toward Persons With Alzheimer's Disease Dementia: Results of a Survey of the U.S. General Public. <i>Health Communication</i> , 2018, 33, 264-273.	3.1	35
65	Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults. <i>JAMA Neurology</i> , 2018, 75, 44.	9.0	54
66	Relationships Between Cognitive Complaints and Quality of Life in Older Adults With Mild Cognitive Impairment, Mild Alzheimer Disease Dementia, and Normal Cognition. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 276-283.	1.3	86
67	Study partners: essential collaborators in discovering treatments for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 101.	6.2	29
68	Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson's Disease</i> , 2018, 4, 19.	5.3	110
69	The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer's Disease Biomarkers. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 485-498.	0.9	19
70	African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 57-64.	3.7	71
71	A Trial of Financial and Social Incentives to Increase Older Adults' Walking. <i>American Journal of Preventive Medicine</i> , 2017, 52, e123-e130.	3.0	43
72	Parkinsonian signs are a risk factor for falls. <i>Gait and Posture</i> , 2017, 55, 1-5.	1.4	11

#	ARTICLE	IF	CITATIONS
73	A Typical Day With Mild Cognitive Impairment. American Journal of Public Health, 2017, 107, 927-928.	2.7	2
74	Expanding engagement with the ethical implications of changing definitions of Alzheimer's disease. Lancet Psychiatry, 2017, 4, e6-e7.	7.4	8
75	Alzheimer's disease: The next frontier—Special Report 2017. Alzheimer's and Dementia, 2017, 13, 374-380.	0.8	88
76	Prognosis Communication in Late-Life Disability: A Mixed Methods Study. Journal of the American Geriatrics Society, 2017, 65, 2496-2501.	2.6	4
77	Awareness of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia Diagnoses Associated With Lower Self-Ratings of Quality of Life in Older Adults. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2017, 72, 974-985.	3.9	67
78	APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Medicine, 2017, 14, e1002254.	8.4	110
79	Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach. Trials, 2017, 18, 474.	1.6	5
80	Study partners should be required in preclinical Alzheimer's disease trials. Alzheimer's Research and Therapy, 2017, 9, 93.	6.2	22
81	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.8	23
82	Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care. AJOB Empirical Bioethics, 2016, 7, 106-115.	1.6	16
83	Cognitive, social, and neural determinants of diminished decision-making and financial exploitation risk in aging and dementia: A review and new model. Journal of Elder Abuse and Neglect, 2016, 28, 320-344.	1.1	69
84	Identifying an appropriate measurement modeling approach for the Mini-Mental State Examination.. Psychological Assessment, 2016, 28, 125-133.	1.5	5
85	Unfinished Business in Preventing Alzheimer Disease. JAMA Internal Medicine, 2016, 176, 1739.	5.1	7
86	Research consent capacity varies with executive function and memory in Parkinson's disease. Movement Disorders, 2016, 31, 414-417.	3.9	12
87	Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. Neurobiology of Aging, 2016, 39, 147-153.	3.1	35
88	Acute stroke trials without informed consent. Neurology, 2016, 86, 1472-1473.	1.1	1
89	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimer's and Dementia, 2016, 12, 614-622.	0.8	42
90	A review of ethical issues in dementia. International Psychogeriatrics, 2015, 27, 1635-1647.	1.0	38

#	ARTICLE	IF	CITATIONS
91	Ascertaining Subjective Cognitive Decline: A Comparison of Approaches and Evidence for Using an Age-Anchored Reference Group. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S43-S55.	2.6	39
92	Statin Therapy and Risk of Acute Memory Impairment. <i>JAMA Internal Medicine</i> , 2015, 175, 1399.	5.1	55
93	Examining the Pathways Between Self-Awareness and Well-Being in Mild to Moderate Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1297-1306.	1.2	13
94	Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. <i>Neurology</i> , 2015, 84, 1488-1494.	1.1	49
95	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 26.	6.2	106
96	Cognitive Aging. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2121.	7.4	96
97	The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment. <i>Social Science and Medicine</i> , 2015, 143, 117-127.	3.8	59
98	The A4 Study: Stopping AD Before Symptoms Begin?. <i>Science Translational Medicine</i> , 2014, 6, 228fs13.	12.4	588
99	Unwrapping A Fragile Concept The Alzheimer Conundrum By Lock Margaret Princeton (NJ) : Princeton University Press , 2014 328App., \$29.95. <i>Health Affairs</i> , 2014, 33, 718-719.	5.2	1
100	Researchers'™ perspectives on the role of study partners in dementia research. <i>International Psychogeriatrics</i> , 2014, 26, 1649-1657.	1.0	21
101	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer's and Dementia</i> , 2014, 10, 477.	0.8	167
102	Cognitive correlates of metamemory in Alzheimer's™ disease.. <i>Neuropsychology</i> , 2014, 28, 695-705.	1.3	18
103	P2-229: WHICH SELF-REPORTED COGNITIVE DIFFICULTIES DIFFERENTIATE COGNITIVELY NORMAL OLDER ADULTS FROM THOSE WITH MCI?. , 2014, 10, P558-P559.		0
104	P4-069: DEVELOPMENT OF A PROCESS TO DISCLOSE AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL OLDER ADULT RESEARCH PARTICIPANTS. , 2014, 10, P808-P808.		0
105	What Latino Puerto Ricans and non-Latinos say when they talk about Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 161-170.	0.8	23
106	Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. <i>Neurology</i> , 2011, 77, 1487-1493.	1.1	113
107	Desktop Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2061-2.	7.4	10
108	Interpreting the Clinical Significance of Capacity Scores for Informed Consent in Alzheimer Disease Clinical Trials. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 568-574.	1.2	38

#	ARTICLE	IF	CITATIONS
109	The Views of Alzheimer Disease Patients and Their Study Partners on Proxy Consent for Clinical Trial Enrollment. American Journal of Geriatric Psychiatry, 2008, 16, 240-247.	1.2	55
110	How redesigning AD clinical trials might increase study partnersâ€™ willingness to participate. Neurology, 2008, 71, 1883-1888.	1.1	65
111	Policy statement on voting by persons with dementia residing in long-term care facilities. , 2006, 2, 243-245.		6